Document:

Revised Form of Indemnification Agreement

 EXHIBIT 10.2 
 INDEMNIFICATION AGREEMENT 
 THIS AGREEMENT is made the
         day of             , 20    , by and between Dresser-Rand Group Inc., a Delaware corporation (the
“Corporation”), and                      (the “Indemnitee”), who serves as [a director/an officer/an employee] of
the Corporation. 
 WHEREAS, the Indemnitee has been appointed to serve in the capacity described above; 

WHEREAS, the Corporation wishes the Indemnitee to continue to serve in such capacity and the Indemnitee is willing, under certain
circumstances, to continue in such capacity; 
 WHEREAS, the Corporation has agreed to provide the Indemnitee with the
benefits contemplated in this Agreement. 
 NOW, THEREFORE, in consideration of the Indemnitee’s continued and
future service to the Corporation, the parties agree as follows: 

1.    INDEMNIFICATION. The Corporation agrees to indemnify the Indemnitee to the fullest
extent permitted by Delaware General Corporation Law, as it exists now and as it may be amended in the future to provide additional indemnification for the Indemnitee, subject to the provisions of this Agreement. If the Indemnitee is entitled under
any provision of this Agreement to indemnification by the Corporation for a portion of any Expenses (as defined below), losses, liabilities, judgments, fines, penalties and amounts paid in settlement incurred by the Indemnitee, but not for the total
amount thereof, the Corporation shall nevertheless indemnify the Indemnitee for such portion. 

2.    ADDITIONAL INDEMNIFICATION AND PAYMENT OF EXPENSES. Without limiting the indemnification
provided in Section 1 and subject to the limitations, terms and conditions of this Agreement, including, but not limited to, the limitations in Section 7, the Corporation agrees to: 

a) indemnify the Indemnitee against all judgments for both compensatory and punitive damages, fines, penalties and
settlements incurred in connection with any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (including, but not limited to, any action by or in the right of the Corporation) (a
“Proceeding”), to which the Indemnitee is, was or at any time becomes a party, or is threatened to be made a party, by reason of the fact that the Indemnitee is, was or at any time becomes a director, officer, employee, agent or fiduciary
of the Corporation, or is or was serving or at any time serves at the request of the Corporation as a director, officer, employee, agent, or fiduciary of another corporation, partnership, joint venture, trust or other enterprise or with respect to
any employee benefit plan (or its participants or beneficiaries) of the Corporation or any such other enterprise, in each case if Indemnitee acted in good faith and in a manner he reasonably believed to be in or not opposed to the best interests of
the Corporation, and with respect to any criminal Proceeding, had no reasonable cause to believe his or her conduct was unlawful; provided, however, that with respect to a Proceeding by or in the right of the Corporation, no such indemnification
shall be made in respect of any claim, issue, or matter as to which Delaware law expressly 

 
prohibits such indemnification by reason of any adjudication of liability of Indemnitee to the Corporation, unless and only to the extent that the Court of Chancery of the State of Delaware or
the court in which such action or suit was brought shall determine upon application that, despite the adjudication of liability but in view of all the circumstances of the case, Indemnitee is entitled to indemnification for such costs, judgments,
penalties, fines, liabilities and Expenses as such court shall deem proper, 
 b) pay all costs, charges and
other expenses, including, but not limited to, attorneys’ fees, costs of appearance, attachment and similar bonds (herein referred to as “Expenses”) incurred in connection with the investigation and defense of any action, suit or
proceeding for which indemnification would be available under Section 2(a), and 
 c) pay all Expenses
actually and reasonably incurred or suffered by Indemnitee or on Indemnitee’s behalf if Indemnitee appears as a witness or otherwise incurs legal expenses as a result of or related to Indemnitee’s service as a director or officer of the
Corporation, in any threatened, pending or completed legal, administrative, investigative or other proceeding or matter to which Indemnitee neither is, nor is threatened to be made, a party. 
 Upon written request by Indemnitee for indemnification under clause 2(a) or 2(b), the entitlement of Indemnitee to indemnification (unless ordered by a court order) shall be determined by the following
person or persons who shall be empowered to make such determination (a “Determination”): (a) the Board of Directors of the Corporation by a majority vote of the directors who are not party to such action, suit or proceeding (the
“Disinterested Directors”), whether or not such majority constitutes a quorum; (b) a committee of Disinterested Directors designated by a majority vote of such directors, whether or not such majority constitutes a quorum; (c) if
there are no Disinterested Directors, or if the Disinterested Directors so direct, by Independent Counsel (defined below) in a written opinion to the Board of Directors, a copy of which shall be delivered to Indemnitee; or (d) the stockholders
of the Corporation. Any Expenses incurred by Indemnitee in connection with a request for indemnification or payment of Expenses hereunder, under any other agreement, any provision of the Corporation’s By-laws or any directors’ and
officers’ liability insurance, shall be borne by the Corporation. The Corporation hereby indemnifies Indemnitee for any such Expense and agrees to hold Indemnitee harmless therefrom irrespective of the outcome of the determination of
Indemnitee’s entitlement to indemnification. In no event shall a Determination be required in connection with advancement of Expenses pursuant to Section 5, in connection with indemnification for Expenses incurred as a witness pursuant to
clause 2(c), or incurred in connection with any Proceeding or portion thereof with respect to which the Indemnitee has been successful on the merits or otherwise. Any decision that a Determination is required by law in connection with any other
indemnification of Indemnitee, and any such Determination, shall be made within 30 days after receipt of the Indemnitee’s written request for indemnification. “Independent Counsel” shall: (a) be competent to deliver the opinion
required, (b) not otherwise have performed any services for the Corporation or any of its affiliates or for the Indemnitee within the past three years (other than with respect to matters concerning the rights of a director or officer of the
Corporation under this Agreement or a similar agreement), and (c) be selected by the Corporation with the consent of the Indemnitee, such consent not to be unreasonably withheld. The Corporation shall pay the fees and expenses of such
independent legal counsel. Upon failure of the Board so to select such Independent Counsel or upon failure of Indemnitee so to approve, such 

  
 2 

 
Independent Counsel shall be selected upon application to a court of competent jurisdiction. Subject to Section 8, If a Determination unfavorable to a Indemnitee is made, the Indemnitee
shall have the right to challenge such Determination before a court of competent jurisdiction. 

3.    MAINTENANCE OF D&O INSURANCE. The Corporation currently maintains directors’
and officers’ liability insurance with a limit of coverage in excess of $                         for directors and
officers (the “D&O Policies”). 
 a) So long as the Indemnitee shall continue to serve in any
capacity described in Section 2 and thereafter so long as the Indemnitee shall be subject to any possible action, suit or proceeding by reason of the fact that the Indemnitee served in any of said capacities, the Corporation will purchase and
maintain in effect for the benefit of the Indemnitee one or more valid, binding and enforceable policies of directors’ and officers’ liability insurance providing, in all respects, (i) coverage at least comparable to that provided
pursuant to the D&O Policies in an amount of at least $50,000,000 for directors and officers and (ii) the same rights and benefits accorded to the most favorably insured of the Corporation’s and its subsidiaries’ then current
directors and officers. 
 b) Notwithstanding Section 3(a), the Corporation shall not be required to
maintain directors’ and officers’ liability insurance in effect if such insurance is not reasonably available or if, in the reasonable business judgment of the Board of Directors of the Corporation as it may exist from time to time, either
(i) the premium cost for such insurance is substantially disproportionate to the amount of insurance or (ii) the coverage is so limited by exclusions that there is insufficient benefit provided by such insurance. 

c) If the Corporation, acting under Section 3(b), does not purchase and maintain in effect directors’ and
officers’ liability insurance, the Corporation shall indemnify and hold harmless the Indemnitee to the full extent of the coverage which would otherwise have been provided by the D&O Policies. 

4.    DEFENSE OF CLAIM. With respect to any action, suit or proceeding described in
Section 2, the Corporation may participate therein at its own expense, and may elect to assume the investigation and defense of such action, suit or proceeding with counsel it selects with the consent of the Indemnitee, which consent shall not
be unreasonably withheld. After notice to the Indemnitee from the Corporation of its election to assume the investigation and defense, the Corporation shall not be liable to the Indemnitee under this Agreement for any expenses subsequently incurred
by the Indemnitee in connection with the investigation and defense other than for services requested by the Corporation or the counsel it selected. The Indemnitee shall have the right to employ his own counsel, but the Expenses incurred by the
Indemnitee after notice from the Corporation of its assumption of the investigation and defense shall be at the expense of the Indemnitee, unless (i) the employment of counsel by Indemnitee has been authorized by the Corporation,
(ii) there is a conflict of interest between the Corporation and Indemnitee in the conduct of the defense of such action or (iii) the Corporation shall not within 60 calendar days of receipt of notice from Indemnitee in fact have employed
counsel to assume the defense of the action, in each of which cases the fees and expenses of Indemnitee’s counsel shall be at the expense of the Corporation. 

  
 3 

 5.    ADVANCE PAYMENT OF EXPENSE. The
Indemnitee’s reasonable Expenses incurred in connection with any action, suit or proceeding described in Section 2(a) shall be paid by the Corporation within 30 days after the Corporation has received written statement from or on behalf of
the Indemnitee requesting such payment or payments from time to time. Such statement or statements shall reasonably evidence the expenses and costs incurred by Indemnitee in connection therewith and shall include or be accompanied by an undertaking,
in substantially the form attached as Exhibit 1, by or on behalf of Indemnitee confirming Indemnitee’s obligation under Section 6 to reimburse such amounts, if required thereunder. Indemnitee’s undertaking to reimburse any such
amounts is not required to be secured. The Corporation shall continue to make such payments unless and until there has been a final adjudication by a court of competent jurisdiction establishing that the Indemnitee is not entitled to be indemnified
for such Expenses under this Agreement. 
 6.    INDEMNITEE’S REIMBURSEMENT. The
Indemnitee agrees to reimburse the Corporation for all amounts paid by the Corporation pursuant to Sections 1, 2, 3(c), 4, and 5 of this Agreement in the event and to the extent, but only in the event and only to the extent that there is a final
adjudication by a court of competent jurisdiction establishing that the Indemnitee is not entitled to be so indemnified or to have such Expenses paid by the Corporation. Indemnitee’s entitlement to such Expenses shall include those incurred in
connection with any Proceeding by Indemnitee seeking a judgment in court pursuant to this Agreement (including the enforcement of this provision). 
 7.    LIMITATIONS ON INDEMNIFICATION AND ADVANCEMENT. Notwithstanding anything in the foregoing to the contrary, the Corporation shall not be liable under this Agreement to make
any indemnity payment or advancement of Expenses in connection with any action, suit or proceeding or part thereof (including claims and counterclaims): 
 a) to the extent that payment is actually made, or for which payment is available, to or on behalf of the Indemnitee under an insurance policy, except in respect of any amount in excess of the limits of
liability of such policy or any applicable deductible for such policy [For Director’s Form: or] [For all others: ;] 
 b) to the extent that payment (other than a payment described in paragraph 11 (c)) has or will be made to the Indemnitee by the Corporation otherwise than pursuant to this Agreement[For Director’s
Form: .] [For all others: ; or 
 c) initiated by Indemnitee [For Form in which the officer also
serves as a director: in [his/her] capacity as an officer or employee of the Corporation], except a judicial proceeding pursuant to Section 8 to enforce rights under this Agreement, unless the action, suit or proceeding (or
part thereof) was authorized by the Board of Directors of the Corporation.] 

8.    ENFORCEMENT OF INDEMNITEE’S RIGHTS. The Indemnitee shall have the right to enforce
this Agreement only in the state courts of the State of Delaware if the Corporation either fails to Indemnify the Indemnitee pursuant to Section 1, 2 or 3(c) or fails to 

  
 4 

 
advance Expenses pursuant to Section 5 within 30 days of the receipt of written request to do so from or on behalf of the Indemnitee. The Indemnitee’s Expenses incurred in successfully
establishing his right to indemnification or advancement of Expenses, in whole or in part, in any such action (or settlement thereof) (including any challenge to an unfavorable Determination pursuant to Section 2) shall be paid by the
Corporation. 
 9.    SETTLEMENT. The Corporation shall not be liable to indemnify
the Indemnitee under this Agreement for any amounts paid in settlement of any action, suit or proceeding without its written consent, which consent shall not be unreasonably withheld. The Corporation shall not settle any action, suit or proceeding
which would impose any penalty or limitation on the Indemnitee without the Indemnitee’s written consent, which consent shall not be unreasonably withheld, conditioned or delayed. In the event that consent is not given and the parties hereto are
unable to agree on a proposed settlement, independent legal counsel shall be retained by the Corporation, at its expense, with the consent of the Indemnitee, which consent shall not be unreasonably withheld, conditioned or delayed for the purpose of
determining whether or not the proposed settlement is reasonable under all the circumstances, and if independent legal counsel determines the proposed settlement is reasonable, the settlement may be consummated without the consent of the other
party. 
 10.    CORPORATE SUBROGATION RIGHTS. In the event of any payment under this
Agreement, the Corporation shall be subrogated to the extent of such payment to all of the rights of recovery of the Indemnitee against any person or organization and the Indemnitee shall execute all papers required and shall do everything that may
be reasonably necessary to secure such rights. 
 11.    NON-EXCLUSIVE. Nothing in
this Agreement shall diminish or otherwise restrict, and this Agreement shall not be deemed exclusive of, the Indemnitee’s rights to, (a) indemnification, (b) advancement of Expenses under (i) any provision of the Delaware
General Corporation Law, (ii) the Certificate of Incorporation, (iii) By-Laws of the Corporation, or (iv) otherwise, or (c) compensation, whether cash or equity, paid by the Corporation as consideration for the Indemnitee serving
as a Indemnitee of the Corporation. This Agreement shall not constitute an employment agreement, supersede any employment agreement to which the Indemnitee is a party or create any right of the Indemnitee to continued employment or appointment. No
resignation or termination of the Indemnitee’s position as such shall affect Indemnitee’s rights under this Agreement. 
 12.    NOTICE TO THE CORPORATION. The Indemnitee will promptly notify the Corporation of any threatened, pending or completed action, suit or proceeding against the Indemnitee
described in Section 2. The failure to notify or promptly notify the Corporation shall not relieve the Corporation from any liability which it may have to the Indemnitee otherwise than under this Agreement, and shall relieve the Corporation
from liability hereunder only to the extent the Corporation has been prejudiced. 

  
 5 

 13.    NOTICES. Any notice that is required or
permitted to be given under this Agreement shall be in writing and shall be personally delivered or deposited in the United States mail, certified or registered mail with proper postage prepaid and addressed: 

If to the Corporation: 

Dresser-Rand Group Inc. 
 10205 Westheimer Road 
 West8 Tower, Suite 1000 

Houston, Texas 77042 
 Attn: General Counsel 
 If to the Indemnitee: 

 

			
		    	  

		    	  

		    	  

 Or at such other address as the party may furnish to the other party by ten (10) days’ prior written notice.

 14.    SEPARABILITY. Each of the provisions of this Agreement is a separate and
distinct agreement and independent of the others, so that if any provision shall be held to be invalid or unenforceable for any reason, such invalidity or unenforceability shall not affect the validity or enforceability of the other provisions.

 15.    GOVERNING LAW. This Agreement shall be governed by and construed in
accordance with the laws of the State of Delaware. 
 16.    BINDING EFFECT. This
Agreement shall be binding upon the Indemnitee and upon the Corporation, its successors and assigns, and shall inure to the benefit of the Indemnitee, his heirs, personal representatives and assigns and to the benefit of the Corporation, its
successors and assigns. 
 17.    AMENDMENT AND TERMINATION. No amendment,
modification, termination or cancellation of this Agreement shall be effective unless in writing signed by both parties. 
 18.    ENTIRE AGREEMENT. This Agreement, having an effective date as first written above, contains the entire agreement and understanding of the parties with respect to the
subject matter hereof and supersedes all prior understandings, arrangements, representations, warranties and agreements between the parties, whether oral or written, with respect to the subject matter of this Agreement. This Agreement may be
executed in multiple counterparts, each of which shall be deemed an original, but all of which shall collectively constitute one and the same instrument. Faxed copies shall be given the full force and effect as an original. 

  
 6 

 IN WITNESS WHEREOF, the parties have executed this Agreement. 

 

									
	 INDEMNITEE:
	    	DRESSER-RAND GROUP INC.
	 	    	
	 Name:  
	 	 	    	By:  	    	 
		 		    	Its:  	    	 

  
 7 

 EXHIBIT 1 

UNDERTAKING TO REPAY INDEMNIFICATION EXPENSES 
 I
                                         
                                         
                      , agree to reimburse the Corporation for all expenses paid to me by the Corporation in connection with any
Proceeding (as defined in the Indemnification Agreement dated as of                             
between me and the Corporation), in the event, and to the extent that it shall finally be determined after all appeals by a court of competent jurisdiction that I am not entitled to be indemnified by the Corporation for such expenses. 

 

			
	 Signature
	 	 
	 Typed Name
	 	 
	 Office
	 	 

                         
                            ) ss: 
 Before me
                                         
   , on this day personally appeared
                                        ,
known to me to be the person whose name is subscribed to the foregoing instrument, and who, after being duly sworn, stated that the contents of said instrument is to the best of his/her knowledge and belief true and correct and who acknowledged that
he/she executed the same for the purpose and consideration therein expressed. 
 GIVEN under my hand and official seal at
                , this                  day of
                            , 201    . 

 
  

	
	 
	 Notary Public

 My commission expires: 

  
 8Amendment No.2 to Dialysis Organization Agreement

 Exhibit 10.2 
 CONFIDENTIAL TREATMENT 
 [DELETED] = Portions of this exhibit are subject to a
request for confidential treatment 
 and have been redacted and filed separately with the Securities and Exchange

 Commission. 
 AMENDMENT NO. 2 DIALYSIS ORGANIZATION AGREEMENT NO. 920110141 
  

This Amendment No. 2 (“Amendment No. 2”) to Dialysis Organization Agreement No. 920110141 is entered into effective
as of July 1, 2011 (“Amendment No. 2 Effective Date”) by and between Amgen USA Inc. (“Amgen”), a wholly-owned subsidiary of Amgen Inc., and DaVita Inc. (“Dialysis Center”) (Amgen and Dialysis Center each a
“Party” and together, the “Parties”). 
 WHEREAS, the Parties entered into that certain Dialysis
Organization Agreement No. 920110141, effective January 1, 2011 (“Agreement”); and 
 WHEREAS, the
Parties amended the Agreement pursuant to Amendment No. 1, dated March 23, 2011 and effective March 31, 2011; and 
 WHEREAS,
the Parties mutually desire to amend the Agreement as stated below. 
 NOW THEREFORE, in consideration of the premises and
of the mutual promises and covenants set forth herein, and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties hereto agree as follows: 

SECTION 1. Definitions; References. Unless otherwise specifically defined herein, each term used herein which is defined in
the Agreement shall have the meaning assigned to such term in the Agreement. Except as amended and supplemented hereby, all of the terms of the Agreement are incorporated herein by reference, shall continue in full force and effect and are hereby
ratified and confirmed in all respects. 
 SECTION 2. Amendment of the Information Sheet of the Agreement. As of the
Amendment No. 2 Effective Date, the Term End Date set forth on the Information Sheet is hereby amended and restated as follows: 
 TERM END DATE: December 31, 2011 
 SECTION 3. Amendment and
Restatement of Section 8.1 of the Agreement. As of the Amendment No. 2 Effective Date, Section 8.1 of the Agreement entitled “Term” is hereby amended and restated as follows: 

 

	 	8.1.	 Term. This Agreement shall come into effect as of the Term Start Date and shall expire as of the Term End Date (the “Term”), unless
sooner terminated in accordance with this Section 8 or superseded and replaced by a new agreement that is executed prior to the Term End Date. 

 SECTION 4. Amendment and Restatement of Section 1.15 of the Agreement. As of the Amendment No. 2 Effective Date with respect to periods commencing on the Amendment No. 2
Effective Date but not periods prior to the Amendment No. 2 Effective Date, Section 1.15 of the Agreement entitled “Quarter” is hereby amended and restated as follows: 

 

	 	1.15	 “Quarter” shall mean each calendar quarter during the Term (i.e., January 1 through March 31, April 1
through June 30, July 1 through September 30 or October 1 through December 31). 

 AMENDMENT NO. 2 DIALYSIS ORGANIZATION AGREEMENT NO. 920110141 

 
  

 SECTION 5. Amendment of Exhibit A. As of the Amendment No. 2 Effective
Date, Exhibit A of the Agreement entitled “Discount Terms and Conditions” is hereby deleted from the Agreement in its entirety and is replaced with Exhibit A attached hereto as Attachment 1 to this Amendment No. 2. 

Except as specifically amended herein, all general terms and conditions of the Agreement remain unchanged and in full force and effect.

  
 The parties executed this amendment to the Agreement as
of the dates set forth below. 
  
  

									
	 Amgen USA Inc.
	 		 	 DaVita Inc.

					
	 Signature:
	 	 /s/ Fred Manak
	 		 	 Signature:
	 	 /s/ Dennis L. Kogod

					
	 Print Name:
	 	 Fred Manak
	 		 	 Print Name:
	 	 Dennis L. Kogod

					
	 Print Title:
	 	 Exec Director Trade, Pricing & Contract Management
	 		 	 Print Title:
	 	 Chief Operating Officer

					
	 Date:
	 	 5/2/11
	 		 	 Date:
	 	
5/2/11                             
       

 Amgen Inc. agrees to be bound by certain provisions of this amendment to the Agreement as set forth
herein 
 Amgen Inc. 
  

					
	 Signature:
	 	 /s/ Fred Manak

		
	 Print Name:
	 	 Fred Manak

		
	 Print Title:
	 	
Exec Director Trade, Pricing & Contract Management

			
	 Date:
	 	
5/2/11                             
                               
	 	

  
 Page 2 of 11

 AMENDMENT NO. 2 DIALYSIS ORGANIZATION AGREEMENT NO. 920110141 

 
  

 ATTACHMENT 1 
 Exhibit A 
 Discount Terms and Conditions 

 

	 	1	 DEFINITIONS. In addition to the defined terms set forth in Section 1 of this Agreement, the following terms, as used in this
Exhibit A, shall have the meaning ascribed below. 

 Special [DELETED] Rebate
Definitions 
  

	 	1.1	 “[DELETED]” shall mean, at any date of determination, [DELETED] as of such date. 

 

	 	1.2	 “Discounts” shall mean all rebates and discounts set forth in this Agreement that may be earned by the Dialysis Center Purchasers
pursuant to the terms and conditions set forth in this Agreement, which shall be earned, calculated and vested as provided in this Agreement. 

  

	 	1.3	 “[DELETED]” shall mean [DELETED] percent ([DELETED]%) [DELETED] as of May 2, 2011, which is $[DELETED] per [DELETED] units of EPOGEN, or
$[DELETED]. 

  

	 	1.4	 “Special [DELETED] Rebate” shall mean the rebate described in Section 3.2 of this Exhibit A.

  

	 	1.5	 “Special [DELETED] Rebate Percentage” shall mean, at any date of determination, a percentage (rounded to two decimal places) to
calculate any Special [DELETED] Rebate to be paid to Dialysis Center on account of [DELETED] increase for the [DELETED] during which such [DELETED] occurs, which Special [DELETED] Rebate Percentage shall equal: 

 

			
		 	 A - B * C

		 	  
    A

 Where 

“A” equals [DELETED] 
 “B” equals [DELETED] 
 “C” equals [DELETED]
([DELETED]) minus the Discounts earned by Dialysis Center Purchasers during such [DELETED], expressed as a percentage of Qualified Gross Purchases 
 For example, if [DELETED] is $[DELETED], [DELETED] is $[DELETED] and the Discounts earned during the applicable [DELETED] are [DELETED]% of Qualified Gross Purchases for such [DELETED], the Special [DELETED]
Rebate Percentage would be calculated as follows: 
 Special [DELETED] Rebate Percentage Illustration: 

 

	
	  
 [DELETED] – [DELETED] * ([DELETED] – Discount %)

[DELETED]                      
          
  
 or
  

$[DELETED] - $[DELETED] * ([DELETED] - [DELETED]) = [DELETED]%
 $[DELETED]                                 
   
  

  
 Page 3 of 11

 AMENDMENT NO. 2 DIALYSIS ORGANIZATION AGREEMENT NO. 920110141 

 
  

 Quality Rebate Definitions 

 

	 	1.6	 “Aggregate [DELETED] Than [DELETED] Baseline Performance” shall mean [DELETED]% for the period of July 1, 2011 through
September 30, 2011 and [DELETED]% for the period of October 1, 2011 through December 31, 2011. 

  

	 	1.7	 “Aggregate [DELETED] Than [DELETED] Percentage” shall mean for any [DELETED] during the Term, the percentage of Dialysis Center
Purchasers’ patients with hemoglobin values greater than [DELETED] g/dL calculated as set forth in Section 3.3.3 of this Exhibit A. 

 

	 	1.8	 “Aggregate [DELETED] Than [DELETED] Baseline Performance” shall mean [DELETED]% for the period of July 1, 2011 through
September 30, 2011 and [DELETED]% for the period of October 1, 2011 through December 31, 2011. 

  

	 	1.9	 “Aggregate [DELETED] Than [DELETED] Percentage” shall mean for any [DELETED] during the Term, the percentage of Dialysis Center
Purchasers’ patients with hemoglobin values less than [DELETED] g/dL calculated as set forth in Section 3.3.4 of this Exhibit A. 

 

	 	1.10	 “[DELETED] Than [DELETED] Requirement Rebate Score” shall mean for any [DELETED] in calendar year 2011, the “Earned Rebate
Score” (as designated in the [DELETED] Than [DELETED] Requirement Rebate Score Table below) multiplied by [DELETED] ([DELETED]). The Earned Rebate Score shall be determined by calculating the difference between (A) the
Aggregate [DELETED] than [DELETED] Percentage for such [DELETED] and (B) Aggregate [DELETED] Than [DELETED] Baseline Performance. 

  

			
	  
 [DELETED] Than [DELETED] Requirement Rebate Score Table

	  

Aggregate [DELETED] Than
 [DELETED] Percentage
  
 minus Aggregate [DELETED] Than
 [DELETED] Baseline
Performance
	  	Earned Rebate Score
	  

[DELETED]% and below
	  	[DELETED]
	  

[DELETED]% - [DELETED]%
	  	[DELETED]
	  

[DELETED]% - [DELETED]%
	  	[DELETED]
	  

[DELETED]% - [DELETED]%
	  	[DELETED]
	  

[DELETED]% - [DELETED]%
	  	[DELETED]
	  

[DELETED]% and above
	  	[DELETED]

  

	 	1.11	 “[DELETED] Than [DELETED] Requirement Rebate Score” shall mean for any [DELETED] in calendar year 2011, the “Earned Rebate
Score” (as designated in the [DELETED] Than [DELETED] Requirement Rebate Score Table below) multiplied by [DELETED] ([DELETED]). The Earned Rebate Score shall be determined by calculating the difference between (A) the
Aggregate [DELETED] than [DELETED] 

  
 Page 4 of 11

 AMENDMENT NO. 2 DIALYSIS ORGANIZATION AGREEMENT NO. 920110141 

 
  

	 	 
Percentage for such [DELETED] and (B) the Aggregate [DELETED] Than [DELETED] Baseline Performance. 

 

			
	  
 [DELETED] Than [DELETED] Requirement Rebate Score Table

	  

Aggregate [DELETED] Than
 [DELETED] Percentage
  
 minus Aggregate [DELETED] Than
 [DELETED] Baseline
Performance
	  	 Earned
Rebate Score
  

	  

[DELETED]% and below
	  	[DELETED]
	  

[DELETED]% - [DELETED]%
	  	[DELETED]
	  

[DELETED]% - [DELETED]%
	  	[DELETED]
	  

[DELETED]% - [DELETED]%
	  	[DELETED]
	  

[DELETED]% - [DELETED]%
	  	[DELETED]
	  

[DELETED]% and above
	  	[DELETED]

  

	 	1.12	 “Quality Rebate” shall mean the rebate described in Section 3.3 of this Exhibit A. 

 

	 	1.13	 “Total Quality % Score” shall mean for any [DELETED] occurring during calendar year 2011, a percentage equal to (i) the sum of,
for such [DELETED], (A) the [DELETED] Than [DELETED] Requirement Rebate Score plus (B) the [DELETED] Than [DELETED] Requirement Rebate Score, divided by (ii) [DELETED] ([DELETED]) (i.e., the maximum
achievable [DELETED] Than [DELETED] Requirement Rebate Score and [DELETED] Than [DELETED] Requirement Rebate Score for such [DELETED]). For the avoidance of doubt, for purposes of calculating Total Quality % Score for the Term, no Dialysis Center
Purchasers which have been added or removed during the Term shall be included in the Aggregate [DELETED] than [DELETED] Percentage or the Aggregate [DELETED] than [DELETED] Percentage of such calculation and the Aggregate [DELETED] Than [DELETED]
Baseline Performance and the Aggregate [DELETED] Than [DELETED] Baseline Performance shall remain unchanged. 

  

	 	2	 [DELETED]. The rebates Dialysis Center may be eligible to receive as set forth in this Exhibit A are subject to the following [DELETED].

  

	 	2.1	 [DELETED]. The rebates set forth in this Exhibit A shall only be paid to Dialysis Center on aggregate Qualified Gross Purchases
made during any [DELETED] that do not [DELETED] percent ([DELETED]%) of the aggregate Qualified Gross Purchases made in the immediately preceding [DELETED]. Such calculation shall be adjusted pursuant to Sections 2.2 and 3.4 of the
Agreement to reflect any Dialysis Center Purchasers added or removed during such period and to remove from the calculation the effect of any change in [DELETED] during the relevant comparison periods. 

 

	 	2.2	 Amgen may, in its sole discretion, determine that Dialysis Center may be eligible to receive rebates on Qualified Gross Purchases [DELETED] percent
([DELETED]%) if such Qualified Gross Purchases are predicated upon [DELETED] in actual [DELETED] and [DELETED] in the [DELETED] of [DELETED]. Amgen shall make such determination based upon a review of all relevant reports including, but not limited
to: monthly forecast reports, the national accounts monthly purchase reports, historical 

  
 Page 5 of 11

 AMENDMENT NO. 2 DIALYSIS ORGANIZATION AGREEMENT NO. 920110141 

 
  

	 	 
purchase reports, appropriate wholesaler data, and any finance reports. Such determination must be approved by Amgen’s Corporate Accounts Senior Management. 

 

	 	3	 PRODUCT REBATES 

  

	 	3.1	 Base Rebate.   Dialysis Center shall earn the Base Rebate for each [DELETED] during the Term as described below in this
Section 3.1 of this Exhibit A. 

3.1.1    Calculation of Base Rebate.   Dialysis Center shall
receive a [DELETED] percent ([DELETED]%) base rebate payment (the “Base Rebate”). The Base Rebate will be calculated as a percentage of the Qualified Gross Purchases during each [DELETED]. 

3.1.2    Payment of Base Rebate.   Amgen will pay the Base Rebate
within [DELETED] ([DELETED]) days after the end of the corresponding [DELETED]. 

3.1.3    Vesting of Base Rebate.   The Base Rebate for a given
[DELETED] shall vest on the last day of such [DELETED]. 
  

	 	3.2	 Special [DELETED] Rebate.    Dialysis Center shall earn the Special [DELETED] Rebate for each [DELETED] during the Term in
the manner described below in this Section 3.2 of this Exhibit A. 

 3.2.1    Trigger Event for Special [DELETED] Rebate.  If within any [DELETED] during the Term, Amgen [DELETED] by an amount which causes [DELETED] to exceed [DELETED],
then Dialysis Center Purchasers shall be entitled to the Special [DELETED] Rebate as calculated in Section 3.2.2 of this Exhibit A. The Special [DELETED] Rebate shall apply to all Qualified Gross Purchases from the date of the related
[DELETED] until the date (if any) at which [DELETED] is [DELETED] to or [DELETED] during the Term. 
 3.2.2    Calculation of Special [DELETED] Rebate.  Amgen shall determine the amount of Dialysis Center’s Special [DELETED] Rebate for any [DELETED] by calculating
the product of (i) Qualified Gross Purchases during such [DELETED] which purchases have been made while [DELETED] and (ii) the Special [DELETED] Rebate Percentage for such [DELETED]. 

3.2.3    Payment of Special [DELETED] Rebate. Amgen will pay the Special
[DELETED] Rebate within [DELETED] ([DELETED]) days after the end of the corresponding [DELETED]. 

3.2.4    Vesting of Special [DELETED] Rebate.    The
Special [DELETED] Rebate for a given [DELETED] shall vest on the last day of such [DELETED]. 
  

	 	3.3	 Quality Rebate.   Dialysis Center shall earn the Quality Rebate for each [DELETED] during the Term provided Dialysis Center
Purchasers meet the requirements described below in this Section 3.3 of this Exhibit A. 

 3.3.1    Qualification Criteria.  To receive a Quality Rebate on Qualified Gross Purchases during a [DELETED], Dialysis Center Purchasers must submit all hemoglobin test
results for each dialysis patient and the date of each such test, as set forth in Schedule 1 of this Agreement, from at least [DELETED] percent ([DELETED]%) of all Dialysis Center Purchasers in accordance with the submission of data requirement set
forth in Section 3.4.1 of this Exhibit A; provided, however, that if such [DELETED] percent ([DELETED]%) threshold is not met in any month due to the inclusion of de novo facilities that have not yet treated patients
and/or inactive facilities, Amgen shall 

  
 Page 6 of 11

 AMENDMENT NO. 2 DIALYSIS ORGANIZATION AGREEMENT NO. 920110141 

 
  

 
exclude any such facilities identified by Amgen and Dialysis Center from such month when calculating Dialysis Center’s eligibility for the Quality Rebate at the end of each [DELETED]. For
purposes of clarity, the [DELETED] percent ([DELETED]%) will not include Dialysis Center Purchasers that are acute facilities. 
 3.3.2    Calculation of Average Patient Hemoglobin.    Each calendar month during the Term, Amgen shall determine the average hemoglobin value for each patient
of Dialysis Center Purchasers by adding all hemoglobin value test results for each such patient of Dialysis Center Purchasers during each such calendar month based on the Data provided by Dialysis Center to Amgen and dividing the sum by the number
of tests for the hemoglobin value of each such patient of Dialysis Center Purchasers performed by the Dialysis Center Purchasers during each such calendar month (the “Individual Patients with Hemoglobin Averages”). Each hemoglobin
test for a patient must be derived from blood samples taken using any automated red blood cell counter testing method (e.g. Coulter-counter, Bayer-Technicon, Sysmex, CellDyne, etc.) given immediately prior to any dialysis treatment for such patient.
Each test result must be reported to the nearest tenth of one gram per deciliter (0.1 g/dL). 

3.3.3    Aggregate [DELETED] Than [DELETED] Percentage
Calculation.      Each [DELETED] the Aggregate [DELETED] than [DELETED] Percentage shall be calculated by adding all Individual Patients with Hemoglobin Averages in each calendar month that are greater than
[DELETED] g/dL and dividing the sum by the total number of Individual Patients with Hemoglobin Averages for that calendar month (the “Monthly [DELETED] Than [DELETED] Percentage”). The Monthly [DELETED] than [DELETED] Percentage for
each calendar month during a [DELETED] are then added and divided by [DELETED] ([DELETED]) to determine the “Aggregate [DELETED] Than [DELETED] Percentage” for such [DELETED]. 

3.3.4    Aggregate [DELETED] Than [DELETED] Percentage
Calculation.      Each [DELETED] the Aggregate [DELETED] than [DELETED] Percentage shall be calculated by adding all Individual Patients with Hemoglobin Averages in each calendar month that are less than [DELETED]
g/dL and dividing the sum by the total number of Individual Patients with Hemoglobin Averages for that calendar month (the “Monthly [DELETED] Than [DELETED] Percentage”). The Monthly [DELETED] Than [DELETED] Percentage for each
calendar month during a [DELETED] are then added and divided by [DELETED] ([DELETED] to determine the “Aggregate [DELETED] Than [DELETED] Percentage” for such [DELETED]. 

3.3.5    Calculation of Quality Rebate.   For each [DELETED],
Amgen shall calculate the amount of Dialysis Center’s Quality Rebate by multiplying Qualified Gross Purchases during such [DELETED] by the applicable Quality Rebate Percentage set forth in the Quality Rebate Table below corresponding to
the applicable Total Quality % Score for such [DELETED]. 

  
 Page 7 of 11

 AMENDMENT NO. 2 DIALYSIS ORGANIZATION AGREEMENT NO. 920110141 

 
  

 
			
	  
 Quality Rebate Table

	  
 Total Quality % Score
	 	  
 Quality Rebate Percentage

	  
 [DELETED]% - [DELETED]%
	 	  
 [DELETED]%

	  
 [DELETED]% - [DELETED]%
	 	  
 [DELETED]%

	  
 [DELETED]% - [DELETED]%
	 	  
 [DELETED]%

	  
 [DELETED]% - [DELETED]%
	 	  
 [DELETED]%

	  
 [DELETED]% and below
	 	  
 [DELETED]%

 3.3.6    Payment of Quality
Rebate.      Amgen will pay the Quality Rebate within [DELETED] ([DELETED]) days after the end of the corresponding [DELETED]. 

3.3.7    Vesting of Quality Rebate.   The Quality Rebate
for a given [DELETED] shall vest on the last day of such [DELETED]. 
  

	 	3.4	 [DELETED] Rebate.    Dialysis Center shall qualify for the [DELETED] Rebate (the “[DELETED] Rebate”) for a given
[DELETED] provided all Dialysis Center Purchasers provide to Amgen the Data set forth in Schedule 1, and provided Dialysis Center meets the requirements described below in this Section 3.4 of this Exhibit A.

 3.4.1    Submission of Data
Requirement.    Subject to the validity of a Certification as described in Section 4 of this Agreement, Dialysis Center Purchasers must provide to Amgen the Data in a machine readable format acceptable to Amgen
(Excel; or text file that is tab delimited, comma delimited, colon delimited or space delimited including a line of column headers identifying the column contents and units, if applicable). The Data files shall contain record counts for each file
contained in the data submission; provided, however, that Dialysis Center shall be required to submit such test results only for those dialysis patients whose test results are actually determined by laboratories owned and operated by Dialysis
Center. 
 3.4.2    Calculation of [DELETED]
Rebate.    Provided Dialysis Center has fulfilled all requirements described in this Section 3.4 of this Exhibit A, Dialysis Center shall be eligible to receive a [DELETED] percent ([DELETED]%) [DELETED]
Rebate payment. The [DELETED] Rebate will be calculated as a percentage of the Qualified Gross Purchases during each [DELETED]. 
 3.4.3    Payment of [DELETED] Rebate.    The Data must be submitted, on a calendar monthly basis by the last day of the following calendar month (or the next
business day if such last day is not a business day). If the Data is received after such timeframe for any month within a given [DELETED], the total Qualified Gross Purchases during such month will be excluded from the calculation of the [DELETED]
Rebate for that [DELETED]. Notwithstanding the foregoing, if Amgen receives all required Data from a minimum of [DELETED] percent ([DELETED]%) of all Dialysis Center Purchasers within the time frame referenced above for any calendar month within a
given [DELETED], the total Qualified Gross Purchases during such calendar month, will be included in the calculation of the [DELETED] Rebate for that [DELETED]; provided that for purposes of clarity, the [DELETED] percent ([DELETED]%)
will not include Dialysis Center Purchasers that are acute facilities. Failure of Dialysis Center to qualify under this Section 3.4 of this Exhibit A during a particular [DELETED] shall not affect Dialysis Center’s
eligibility to qualify during any 

  
 Page 8 of 11

 AMENDMENT NO. 2 DIALYSIS ORGANIZATION AGREEMENT NO. 920110141 

 
  

 
other [DELETED], nor shall Dialysis Center’s qualification during a particular [DELETED] automatically result in qualification during any other [DELETED]. If Amgen receives all required Data
from less than [DELETED] percent ([DELETED]%) of Dialysis Center Purchasers for any calendar month within a given [DELETED], no Qualified Gross Purchases during such calendar month will be included in the calculation of the [DELETED] Rebate for that
[DELETED]; provided, however, that if such [DELETED] percent ([DELETED]%) threshold is not met in any month due to the inclusion of de novo facilities that have not yet treated patients and/or inactive facilities, Amgen shall exclude any such
facilities identified by Amgen and Dialysis Center from such month when calculating Dialysis Center’s eligibility for the [DELETED] Rebate at the end of each [DELETED]. However, if Amgen determines that any Dialysis Center Purchaser is
consistently not submitting the required Data, Amgen and Dialysis Center will work collaboratively in resolving such inconsistencies. Amgen will use commercially reasonable efforts to notify Dialysis Center in writing, no later than fifteen
(15) business days after the receipt and acceptance by Amgen of the Data of the identity of all Designated Affiliates and/or Designated Managed Centers, if any, which have failed to meet the Data submission requirements for that month. Amgen
reserves the right, in its sole discretion, to exclude any Qualified Gross Purchases of any Designated Affiliate and/or Designated Managed Center that is consistently non-reporting from the calculation of the [DELETED] Rebate for any relevant
[DELETED]. Amgen will pay such [DELETED] Rebate within [DELETED] ([DELETED]) days after the end of the corresponding [DELETED] provided Amgen is in receipt of all Data in the form and in the time period described in Section 3.4.1 of this
Exhibit A. If the failure of Dialysis Center to deliver any such Data is a result of a Certification not being valid due to Amgen’s failure to satisfy any Certification Requirement (as described in Section 4 of this
Agreement) then the [DELETED] Rebate shall still be available to Dialysis Center and payable by Amgen, in which case Dialysis Center shall deliver the Data to Amgen as soon as the Certification becomes valid. Upon a valid Certification being issued,
Dialysis Center shall submit to Amgen all Data dating back to the date Dialysis Center stopped submitting the Data to Amgen within thirty (30) days. 

3.4.4    Vesting of [DELETED] Rebate.   The [DELETED] Rebate for
a given [DELETED] shall vest on the last day of such [DELETED]. 
  

	 	3.5	 [DELETED] Milestone Rebate.     Dialysis Center shall qualify for the [DELETED] [DELETED] Milestone Rebate (the
“[DELETED] Rebate”) for each [DELETED] during the Term provided it meets the requirements described below in this Section 3.5 of this Exhibit A. The purpose of the [DELETED] Rebate is to improve the transmission, quality
and validation of all Data sent from Dialysis Center to Amgen, such that the processes used by both parties are more efficient and timely. 

3.5.1   Requirements.   For each [DELETED] during the Term the
following requirements shall be met to earn the [DELETED] Rebate: 
 3.5.1.1 Dialysis Center must
adhere to the process for Data transmission agreed upon with Amgen following any acquisition of a facility or facilities by Dialysis Center and/or a merger of Dialysis Center. 

3.5.1.2 Dialysis Center shall participate in quarterly [DELETED] meetings with Amgen to discuss the status
of each project, with additional meetings as required. 

  
 Page 9 of 11

 AMENDMENT NO. 2 DIALYSIS ORGANIZATION AGREEMENT NO. 920110141 

 
  

 3.5.1.3 Dialysis Center shall cooperate with Amgen to
define roles and responsibilities, contacts, and communication escalation process. 
 3.5.1.4
Dialysis Center shall adhere to the process for mapping revised patient IDs to previous patient IDs whenever identification systems change. 
 3.5.1.5   Dialysis Center shall collaborate with Amgen to review and monitor processes to assure that submission of the Data contained in this Exhibit A meet standards for [DELETED] or
[DELETED] for [DELETED] and [DELETED] submission, and the use of [DELETED] and [DELETED] for [DELETED] and [DELETED] submissions. 
 3.5.1.6   Dialysis Center shall use its best efforts to deliver the Data to Amgen in twenty-five (25) days or less. 

3.5.1.7   Dialysis Center shall continue to collaborate with Amgen to develop business
processes to re-define limits for out of limits reports and resolve unusual numbers of re-defined out-of-limits Data in submissions. 
 3.5.1.8   Dialysis Center shall adhere to the agreed upon process for notifying Amgen of new Dialysis Center acquisitions and de novo facilities. 

3.5.1.9   To qualify for the [DELETED] Rebate during the [DELETED] and [DELETED] of 2011,
Dialysis Center must achieve the goals as set forth in the plan of action attached hereto as Addendum A. 
 3.5.2   Calculation of [DELETED] Rebate.    Provided Dialysis Center has fulfilled all requirements described in this Section 3.5 of this Exhibit
A, Dialysis Center shall be eligible to receive a [DELETED] percent ([DELETED]%) [DELETED] Rebate payment. The [DELETED] Rebate will be calculated as a percentage of the Qualified Gross Purchases during each [DELETED]. 

3.5.3   Payment of [DELETED] Rebate.  Amgen will pay the [DELETED] Rebate
within [DELETED] ([DELETED]) days after the end of the corresponding [DELETED]. 

3.5.4   Vesting of [DELETED] Rebate.  The [DELETED] Rebate for a given
[DELETED] shall vest on the last day of such [DELETED]. 
  

	 	3.6	 Project Rebate.   Dialysis Center shall earn the Project Rebate for each [DELETED] during the Term provided it continues the
[DELETED] and meets the requirements described below in this Section 3.6 of this Exhibit A. 

 3.6.1   Project Rebate Requirements.      Dialysis Center shall meet the following requirements: 

3.6.1.1 provide to Amgen a [DELETED] written summary report regarding related activities undertaken in the
[DELETED] of 2011. Such report shall be submitted to Amgen within four (4) weeks after the end of the [DELETED] of 2011; 
 3.6.1.2   provide any copies of abstracts and/or manuscripts related to the [DELETED] Program at the time they were [DELETED], if permissible to [DELETED], or if not permissible, then as soon
as [DELETED], if either such abstracts and/or manuscripts were [DELETED] or [DELETED] during the [DELETED] of 2011. Such documents shall be submitted to Amgen within four (4) weeks after the end of the [DELETED] of 2011; 

  
 Page 10 of 11

 AMENDMENT NO. 2 DIALYSIS ORGANIZATION AGREEMENT NO. 920110141 

 
  

 3.6.1.3   provide to Amgen a [DELETED]
written summary report regarding related activities undertaken in the [DELETED] of 2011. Such report shall be submitted to Amgen within four (4) weeks after the end of the [DELETED] of 2011; 

3.6.1.4   provide any copies of abstracts and/or manuscripts related to the [DELETED] at the
time they were [DELETED], if permissible to [DELETED], or if not permissible, then as soon as [DELETED], if either such abstracts and/or manuscripts were [DELETED] or [DELETED] during the [DELETED] of 2011. Such documents shall be submitted to Amgen
within four (4) weeks after the end of the [DELETED] of 2011; and 

3.6.1.5   participate in meetings with Amgen to discuss the status of the [DELETED].

 3.6.2   Calculation of Project Rebate.    Provided
Dialysis Center has fulfilled all requirements described in this Section 3.6 of this Exhibit A, Amgen shall calculate the amount of Dialysis Center’s Project Rebate each [DELETED] during the Term by multiplying Qualified
Gross Purchases during each such [DELETED] during the Term by [DELETED] percent ([DELETED]%). 

3.6.3   Payment of Project Rebate.    Amgen will pay the Project
Rebate within [DELETED] ([DELETED]) days after the end of the corresponding [DELETED]. 

3.6.4    Vesting of Project Rebate.  The Project Rebate for each
[DELETED] shall vest on the last day of each such [DELETED]. 
  

	 	4	 SUMMARY OF DISCOUNTS  

 Provided Dialysis Center has fulfilled all discount requirements and the highest levels of performance described in this Exhibit A, the total discount opportunity is as set forth in the Summary of
Discounts Table below. 
  

			
	Summary of
Discounts Table
	 Invoice Discount
	  	 [DELETED]%

	 Base Rebate
	  	 [DELETED]%

	 Projects Rebate
	  	 [DELETED]%

	 Quality Incentive
Rebate
	  	 [DELETED]%

	 [DELETED] Rebate
	  	 [DELETED]%

	 [DELETED] Rebate
	  	 [DELETED]%

	 Total Discount
Opportunity
	  	 [DELETED]%

  
 Page 11 of 11

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00192-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00192-of-00352.parquet"}]]